about
A molecular switch driving inactivation in the cardiac K+ channel HERGQT is longer in drug-free patients with schizophrenia compared with age-matched healthy subjectsADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockageThe Concise Guide to PHARMACOLOGY 2013/14: ion channelsAge-dependent electrical and morphological remodeling of the Drosophila heart caused by hERG/seizure mutations.hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study.Are hERG channel blockers also phospholipidosis inducers?Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation.Drug-induced hERG block and long QT syndrome.Forward trafficking of ion channels: what the clinician needs to know.Ion channels as novel therapeutic targets in the treatment of pain.A key role for peroxynitrite-mediated inhibition of cardiac ERG (Kv11.1) K(+) channels in carbon monoxide-induced proarrhythmic early afterdepolarizations.AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation.Effect of 4-Aminopyridine on Action Potential Parameters in Isolated Dog Purkinje Fibers.Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.Effects of 4-Aminopyridine on Cloned hERG Channels Expressed in Mammalian Cells.Inflammatory factors that contribute to upregulation of ERG and cardiac arrhythmias are suppressed by CPU86017, a class III antiarrhythmic agent.Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells.
P2860
Q28481507-5C58D23B-18B0-4CB1-97A7-17A96C8486B7Q28539256-5E7124BB-C951-4CD3-821C-638E578AA543Q28730653-D8C5545F-C0F7-4B1A-96FA-17A6BD3B4753Q30486735-4F8D878B-6993-4B8C-B0D0-72B5640CEA74Q33764922-0E2DCDB2-D183-443C-AB0D-01A70C083937Q33845924-C8D5EB0E-F054-4FF7-822F-B9AC9EF3E09EQ33933939-0C6D10FF-A083-4888-BE47-1B677997DB24Q37077945-E7DED6B4-A7C2-4618-8F86-97D37044A2A5Q37579944-5B3168B7-D469-4DA0-8FF6-5BB15EDC72A6Q37734559-D7C49FA2-CA68-4360-8FF9-EDF443156590Q37771741-48D438FC-C445-45B3-A07B-F03C169D644EQ37783350-0E933916-C537-46E8-9882-1D7883262347Q38661585-94F5A21D-B4D8-4FD9-A6B7-802DF38E40E4Q38760655-3836E85E-FA43-4D01-B369-0FFA3FED7808Q40059834-188E9C28-3057-4827-8F1A-D9DB2DD511A1Q41140521-BFDB2A61-AB53-4833-9D5B-DF1762EDF7EDQ41819420-843AACB0-57B5-4768-9E5C-054A5998D114Q46471346-2B7DDE50-5AFE-4BF0-AF18-3A5787DCA9E1Q50884850-4DDAEB81-0D4C-4D81-9F45-8A167750DE0A
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The hERG potassium channel as a therapeutic target.
@ast
The hERG potassium channel as a therapeutic target.
@en
type
label
The hERG potassium channel as a therapeutic target.
@ast
The hERG potassium channel as a therapeutic target.
@en
prefLabel
The hERG potassium channel as a therapeutic target.
@ast
The hERG potassium channel as a therapeutic target.
@en
P2860
P1476
The hERG potassium channel as a therapeutic target.
@en
P2093
Harry J Witchel
P2860
P304
P356
10.1517/14728222.11.3.321
P407
P577
2007-03-01T00:00:00Z